mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes
/ National Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 10, 2025
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
(clinicaltrials.gov)
- P1 | N=155 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)
New P1 trial • Hematological Malignancies • Oncology • Transplantation
November 06, 2025
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
(clinicaltrials.gov)
- P1 | N=155 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Oncology • Transplantation
1 to 2
Of
2
Go to page
1